pharmaceutical-investing Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients
Inventus Provides Operational Update as Trench 1 Bulk Sample Processing Underway and Drilling Continues at the Pardo "River of Gold" Project